coronavirus
cov
known
caus
mild
upper
respiratori
tract
infect
human
paradigm
challeng
sever
acut
respiratori
syndrom
sar
cov
emerg
sarscov
caus
mainli
lower
respiratori
tract
infect
bronchiti
pneumonia
approxim
sarscov
patient
develop
sever
complic
succumb
diseas
viru
origin
bat
transmit
human
civet
cat
highlight
zoonot
capac
spread
worldwid
infect
individu
within
year
fortun
contain
current
evid
sarscov
circul
human
popul
howev
sarslik
cov
abl
directli
infect
human
cell
recent
identifi
horsesho
bat
china
therefor
continu
surveil
virus
remain
necessari
decad
sarscov
epidem
anoth
novel
cov
isol
saudi
arabian
man
present
acut
pneumonia
subsequ
develop
acut
respiratori
distress
syndrom
renal
failur
fatal
outcom
viru
later
call
middl
east
respiratori
syndrom
mer
cov
attract
public
interest
due
resembl
sarscov
far
least
individu
infect
fatal
rate
differ
sar
individu
infect
merscov
remain
asymptomat
develop
mild
clinic
manifest
effort
develop
effect
prevent
therapeut
intervent
strategi
current
ongo
current
intervent
mainli
base
set
surveil
studi
public
health
measur
includ
patient
isol
quarantin
although
action
result
success
contain
sar
outbreak
merscov
still
remain
problem
mainli
arabian
peninsula
widespread
circul
merscov
dromedari
camel
like
drive
forc
outbreak
novel
zoonot
introduct
merscov
may
occur
frequent
therefor
differ
intervent
approach
may
necessari
treat
mer
patient
control
zoonot
nosocomi
transmiss
describ
affect
group
ongo
merscov
outbreak
distinct
intervent
strategi
may
curb
spread
viru
mer
patient
admit
hospit
clinic
symptom
mostli
includ
fever
cough
expector
short
breath
ground
glass
opac
consolid
lung
commonli
report
chest
radiograph
comput
tomographi
scan
howev
characterist
overlap
lower
respiratori
tract
infect
pathognomon
merscov
indic
need
develop
laboratorybas
diagnost
assay
high
sensit
specif
upon
discoveri
merscov
found
replic
high
titer
induc
cytopath
effect
variou
differ
cell
line
thu
enabl
rapid
full
genom
character
two
larg
replicas
open
read
frame
cover
region
merscov
genom
wherea
end
genom
encod
structur
protein
ie
spike
membran
nucleocapsid
n
envelop
e
sever
accessori
protein
nucleotid
sequenc
merscov
use
templat
design
primer
genomebas
assay
ie
realtim
reversetranscript
polymeras
chain
reaction
rtpcr
sequenc
primer
pair
target
region
upstream
e
upe
n
rdrp
gene
develop
shown
highli
sensit
specif
emc
isol
also
merscov
isol
current
suggest
use
upe
rtpcr
screen
assay
anoth
target
gene
confirmatori
assay
despit
highli
specif
sensit
rtpcrbase
assay
still
limit
merscov
detect
activ
shed
host
serologybas
assay
subsequ
develop
distinguish
individu
expos
merscov
past
indirect
immunofluoresc
assay
ifa
neutral
test
plaqu
reduct
neutral
test
microneutr
test
set
use
suscept
cell
line
whole
viru
particl
assay
requir
biosafeti
level
facil
work
infecti
merscov
invitro
limit
usag
addit
whole
viru
ifa
show
limit
specif
merscov
due
crossreact
human
cov
altern
assay
use
pseudoparticl
viru
specif
merscov
antigen
develop
solv
issu
two
cov
structur
protein
known
highli
antigen
n
protein
protein
use
develop
serologybas
assay
variou
platform
ie
recombin
ifa
western
blot
enzymelink
immunosorb
assay
elisa
luciferasebas
antibodi
detect
assay
protein
microarray
n
protein
rel
conserv
among
cov
wherea
domain
locat
diverg
among
cov
make
ideal
candid
cov
specif
diagnost
serolog
assay
howev
import
note
none
serolog
assay
avail
date
fulli
valid
specif
sensit
therefor
due
care
must
taken
interpret
result
larg
serosurveil
studi
possibl
cross
reactiv
andor
low
sensit
assay
lead
failur
determin
preval
true
merscov
posit
case
given
popul
turn
impact
calcul
fatal
rate
viral
infect
studi
use
set
wellcharacter
sera
requir
determin
cutoff
valu
assess
crossreact
merscov
human
cov
crucial
properli
determin
merscov
preval
popul
level
develop
adequ
control
program
one
third
symptomat
patient
develop
sever
pneumonia
ultim
lead
fatal
outcom
gener
individu
character
advanc
age
year
old
may
multipl
underli
comorbid
ie
diabet
mellitu
asthma
chronic
kidney
failur
heart
diseas
immunosuppress
importantli
also
prone
develop
lifethreaten
complic
sepsi
acut
respiratori
distress
syndrom
acut
kidney
failur
therefor
rapid
effect
treatment
option
requir
order
limit
number
case
fatal
outcom
sever
studi
dedic
develop
effect
treatment
merscov
either
base
use
broadspectrum
merscov
specif
therapeut
agent
invitro
merscov
highli
sensit
type
interferon
ifn
merscov
replic
vero
cell
could
effici
reduc
low
level
recombin
case
sarscov
much
higher
concentr
need
achiev
similar
inhibit
viral
replic
broad
spectrum
antivir
ribavirin
mycophenol
acid
cyclosporinea
also
antivir
activ
merscov
invitro
combin
ribavirin
may
synergist
effect
shown
invitro
vivo
studi
rhesu
macaqu
howev
treatment
initi
quit
earli
infect
henc
limit
effect
therapeut
window
opportun
experiment
sarscov
infect
mice
show
administr
type
ifn
h
post
inocul
pi
lifesav
h
pi
detriment
support
limit
effect
therapeut
window
opportun
import
suffici
type
ifn
produc
earli
sarscov
infect
also
investig
experiment
infect
macaqu
advancedag
macaqu
mount
suffici
type
ifn
respons
upon
sarscov
inocul
instead
upregul
express
neutrophil
chemoattract
lead
develop
acut
lung
injuri
ali
importantli
treatment
type
ifn
day
pi
prevent
mediat
ali
limit
effect
therapeut
window
opportun
type
ifn
might
explain
cocktail
regimen
ribavirin
improv
overal
surviv
rate
seen
human
mer
case
despit
promis
invitro
invivo
result
candid
drug
identifi
screen
merscov
inhibitori
activ
use
fdaapprov
drug
use
treat
diseas
two
research
group
report
chloroquin
chlorpromazin
potenti
therapeut
antivir
activ
chlorpromazin
affect
assembl
clathrinco
pit
plasma
membran
chloroquin
play
role
endosom
acidif
interrupt
biolog
process
drug
like
inhibit
merscov
endocytosi
host
cell
membran
fusion
endosom
intracellularli
due
limit
effect
therapeut
window
opportun
broad
spectrum
antivir
agent
might
suffici
treat
sever
merscov
patient
sever
promis
cov
specif
therapeut
agent
recent
review
extens
includ
effort
develop
effect
intervent
measur
aim
disrupt
interact
merscov
host
receptor
dipeptidyl
peptidas
although
crystal
structur
protein
merscov
allow
visual
interact
amino
acid
protein
antagonist
adenosin
deaminas
ada
antibodi
recogn
receptor
bind
domain
rbd
identifi
far
importantli
inhibitor
enzymat
activ
gener
use
treat
type
diabet
patient
block
infect
target
cell
merscov
anoth
potenti
target
treatment
protein
merscov
subdomain
protein
mediat
fusion
viru
endosom
interact
heptad
region
hr
within
protein
imper
merscov
entri
target
cell
interact
disrupt
use
artifici
homolog
peptid
make
promis
entri
inhibitor
merscov
also
novel
drug
aim
inhibit
viru
replic
within
host
cell
target
nonstructur
protein
nsp
coronavirus
exampl
novel
inhibitor
act
pocket
bind
ligand
compound
conserv
among
coronavirus
make
promis
pancoronaviru
replic
inhibitor
mer
patient
requir
proper
quarantin
measur
hinder
spread
merscov
suscept
individu
although
sever
studi
perform
saudi
arabia
south
korea
indic
humantohuman
transmiss
rel
limit
found
crucial
import
especi
hospit
outbreak
ineffici
humantohuman
transmiss
partli
due
tropism
merscov
autopsi
result
one
fatal
human
mer
case
exvivo
experi
use
human
lung
explant
show
viru
infect
lower
respiratori
tract
epithelium
observ
consist
fact
case
merscov
isol
human
sampl
success
lower
respiratori
tract
sampl
use
although
possibl
detect
merscov
upper
respiratori
tract
viral
rna
level
gener
low
compar
lower
respiratori
tract
restrict
tropism
merscov
lower
respiratori
tract
support
distribut
host
receptor
express
lower
upper
human
respiratori
tract
epithelium
result
lower
respiratori
tract
tropism
close
contact
individu
necessari
transmit
merscov
human
healthcar
worker
famili
member
therefor
particular
risk
acquir
secondari
mersinfect
reflect
mer
outbreak
mostli
occur
healthcar
center
group
risk
merscov
infect
slaughterhous
worker
camel
shepherd
cohort
studi
saudi
arabia
qatar
group
camel
contact
report
higher
percentag
merscov
seroposit
compar
gener
popul
fact
camelfarmrel
outbreak
gener
less
common
compar
healthcarerel
outbreak
may
also
help
contain
outbreak
sarscov
outbreak
hong
kong
activ
surveil
follow
proper
quarantin
measur
shown
highli
effect
limit
spread
viru
suscept
individu
one
import
factor
help
contain
outbreak
relat
fact
viru
rare
caus
subclin
infect
viru
excret
peak
approxim
day
onset
symptom
allow
success
contain
sar
patient
diagnos
earli
diseas
onset
recent
data
merscov
outbreak
south
korea
also
show
viral
shed
sever
case
peak
second
week
onset
diseas
therefor
similar
sar
rapid
identif
merscov
patient
follow
proper
quarantin
measur
suffici
significantli
limit
spread
viru
especi
hospit
set
mer
outbreak
occur
inde
strategi
report
use
control
merscov
outbreak
south
korea
like
approach
properli
appli
earlier
outbreak
saudi
arabia
fact
recent
mer
case
report
region
mostli
seem
restrict
primari
case
histori
camel
contact
less
nosocomi
outbreak
may
indic
effect
control
measur
implement
contain
spread
viru
studi
hong
kong
sarscov
outbreak
also
indic
infect
sarscov
unlik
result
asymptomat
infect
explain
activ
surveil
quarantin
effect
stop
outbreak
case
mer
asymptomat
merscovinfect
individu
spread
viru
may
fuel
ongo
outbreak
current
identifi
diagnost
screen
difficult
precis
assess
percentag
asymptomat
merscov
infect
human
popul
partli
due
lack
activ
serolog
surveil
fulli
valid
commerci
serolog
assay
howev
asymptomat
individu
contact
mer
patient
identifi
use
combin
rtpcr
elisa
ifa
prnt
assay
suggest
case
mer
viru
inde
caus
mild
asymptomat
infect
addit
subclin
merscov
infect
long
term
excret
merscov
rna
report
unlik
sever
mer
case
patient
mostli
young
middleag
without
underli
comorbid
group
primarili
domin
health
care
worker
hospit
merscov
patient
admit
secondli
famili
member
close
contact
sever
merscov
patient
one
contact
trace
studi
individu
contact
merscov
patient
conclud
probabl
merscov
infect
one
contact
develop
symptom
later
progress
respiratori
failur
fatal
outcom
rest
report
symptom
therefor
ongo
outbreak
health
care
set
imper
protect
healthcar
worker
high
risk
acquir
infect
scenario
prophylact
regimen
exampl
use
human
monoclon
antibodi
would
theoret
suitabl
limit
spread
viru
monoclon
antibodi
mostli
limit
therapeut
efficaci
despit
promis
invivo
result
yet
might
still
serv
potent
prophylact
measur
exemplifi
palivizumab
monoclon
antibodi
respiratori
syncyti
viru
antibodi
effect
reduc
frequenc
hospit
children
high
risk
infect
efficaci
treatment
purpos
demonstr
receptor
bind
domain
rbd
locat
within
protein
could
serv
target
human
monoclon
antibodi
antibodi
gener
use
differ
approach
ie
nonimmun
human
peripher
blood
mononuclear
cell
yeast
cell
express
human
antibodi
memori
b
cell
obtain
infect
human
mice
immun
rbd
domain
protein
merscov
sever
antibodi
report
effect
invitro
invivo
one
monoclon
antibodi
merscov
shown
effect
prophylact
agent
rabbit
inhibit
viru
attach
could
also
achiev
target
host
receptor
unfortun
commerci
avail
inhibitor
market
type
ii
diabet
mellitu
drug
abl
serv
purpos
sinc
bind
rbd
monoclon
antibodi
target
hand
also
may
inhibit
merscov
attach
vitro
one
antibodi
use
phase
clinic
trial
patient
cancer
also
exampl
antivir
agent
use
prophylact
purpos
postexposur
prophylaxi
use
oseltamivir
shown
effect
reduc
influenza
transmiss
influenza
outbreak
singapor
militari
camp
intranas
pretreat
age
mice
poli
ic
agonist
induc
ifn
express
provid
protect
lethal
dose
sarscov
influenza
viru
besid
prophylact
measur
vaccin
could
also
appli
particular
risk
group
mani
differ
approach
taken
develop
mer
vaccin
review
orthopoxvirusbas
vaccin
use
modifi
vaccinia
ankara
mva
express
spike
protein
develop
shown
induc
neutral
antibodi
specif
cytotox
cell
respons
merscov
mva
valid
effect
vaccin
platform
human
unlik
prophylact
regimen
protect
induc
vaccin
intervent
long
last
although
immedi
thu
vaccin
would
appropri
camel
shepherd
slaughterhous
worker
continu
risk
infect
merscov
anim
zoonot
capac
merscov
suggest
alreadi
begin
emerg
sinc
observ
viru
close
relat
bat
cov
human
cov
bat
suggest
one
natur
host
merscov
evid
support
transmiss
viru
bat
speci
current
lack
serologybas
assay
appli
use
sera
variou
anim
speci
search
anim
host
merscov
reveal
dromedari
camel
like
zoonot
sourc
merscov
high
percentag
seroposit
merscov
among
camel
arabian
peninsula
africa
earli
indic
merscov
circul
anim
long
introduc
human
popul
screen
dromedari
camel
nasal
swab
subsequ
led
identif
isol
merscov
dromedari
confirm
circul
anim
speci
camel
develop
mild
upper
respiratori
tract
infect
upon
experiment
inocul
merscov
consist
local
locat
furthermor
two
studi
human
mer
case
postcontact
infect
camel
report
high
similar
viru
sequenc
obtain
camel
human
studi
along
case
control
studi
identifi
direct
exposur
camel
risk
factor
merscov
infect
serolog
studi
show
higher
seroposit
among
camel
contact
compar
noncamel
contact
support
cameltohuman
transmiss
merscov
risk
human
acquir
merscov
infect
camel
could
high
due
wide
geograph
distribut
merscov
seroposit
camel
also
demonstr
fact
merscov
seroposit
livestock
handler
identifi
kenya
might
underestim
due
unrecord
subclin
infect
human
effort
screen
anim
speci
merscov
current
ongo
phylogenet
analysi
use
rbd
within
differ
speci
identifi
sever
livestock
anim
ie
sheep
goat
cattl
llama
hors
cluster
togeth
suscept
anim
includ
dromedari
camel
transfect
nonsuscept
cell
differ
anim
speci
convert
cell
becom
suscept
merscov
howev
serolog
studi
provid
evid
merscov
circul
anim
experiment
merscov
infect
show
alpaca
shed
infecti
viru
twelv
day
post
inocul
could
transmit
infecti
viru
alpaca
observ
consist
find
studi
farm
locat
al
shahaniya
region
qatar
show
alpaca
found
posit
neutral
antibodi
merscov
alpaca
hous
nearbi
camel
also
seroposit
merscov
taken
care
shepherd
although
pig
llama
found
suscept
merscov
upon
experiment
infect
thu
far
evid
obtain
field
seroconvers
anim
speci
limit
shed
infecti
viru
report
goat
sheep
hors
experiment
inocul
merscov
suggest
anim
play
minim
role
spread
merscov
current
outbreak
studi
suggest
among
livestock
anim
dromedari
camel
main
speci
respons
spread
viru
given
fact
livestock
anim
especi
dromedari
camel
potenti
transmit
merscov
human
prevent
measur
need
appli
reduc
risk
zoonot
transmiss
sar
outbreak
civet
cat
pose
risk
transmit
viru
human
cull
thu
potenti
contribut
limit
outbreak
case
mer
vaccin
base
strategi
appli
reduc
transmiss
viru
human
mvabas
vaccin
merscov
might
suitabl
intervent
strategi
purpos
vaccin
shown
induc
neutral
antibodi
significantli
reduc
merscov
shed
camel
vaccin
strategi
may
especi
appli
young
dromedari
calv
month
postparturit
lose
matern
antibodi
studi
also
address
whether
vaccin
abl
provid
protect
long
term
fact
vaccin
may
provid
addit
protect
camelpox
viru
anoth
pox
viru
could
caus
sever
diseas
camel
taken
account
evalu
costeffect
vaccin
despit
current
implement
rapid
diagnost
public
health
measur
new
merscov
case
still
continu
report
suggest
multipl
intervent
target
differ
affect
group
would
necessari
stop
outbreak
summar
fig
describ
review
differ
intervent
approach
may
need
limit
merscov
outbreak
treat
merscov
patient
control
zoonot
nosocomi
transmiss
prophylact
drug
would
appropri
use
immedi
protect
requir
limit
spread
viru
exampl
protect
health
care
worker
famili
member
merscov
patient
camel
contact
higher
chanc
infect
hand
may
benefit
long
term
protect
induc
vaccin
vaccin
could
also
appli
anim
host
merscov
close
contact
human
mainli
dromedari
camel
limit
zoonot
transmiss
effect
treatment
strategi
sever
human
merscov
patient
problemat
implement
merscov
patient
may
requir
cocktail
treatment
regimen
consist
potent
antivir
immunomodulatori
agent
support
treatment
control
diseas
progress
improv
prognosi
sever
lung
infect
although
type
ifn
remain
promis
treatment
benefici
effect
sever
fatal
merscov
patient
might
limit
due
time
drug
administr
narrow
effect
therapeut
window
opportun
effort
better
understand
merscov
pathogenesi
need
identifi
viral
host
factor
play
signific
role
progress
mer
human
offer
potenti
novel
treatment
intervent
option
